2. Immunology/Inflammation PI3K/Akt/mTOR Epigenetics NF-κB Metabolic Enzyme/Protease Apoptosis
  3. NO Synthase AMPK Keap1-Nrf2 Xanthine Oxidase Apoptosis
  4. Lithospermic acid

Lithospermic acid  (Synonyms: (+)-Lithospermic acid)

Cat. No.: HY-N0823 Purity: 99.42%
COA
SDS
Handling Instructions Technical Support

Lithospermic acid ((+)-Lithospermic acid) is a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza, and has the anti-oxidative and hepatoprotective activity on carbon tetrachloride (CCl4)-induced acute liver damage in vitro and in vivo.

For research use only. We do not sell to patients.

CAS No. : 28831-65-4

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 6 publication(s) in Google Scholar

Other Forms of Lithospermic acid:

Lithospermic acid Related Antibodies

Top Publications Citing Use of Products

    Lithospermic acid purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Feb 20:31:101589.

    CCK8 assay of macrophages treated with various concentrations of ZIF-8, Lithospermic acid (LA, 0-400 μg/mL) and LA@ZIF-8 for 24h.

    Lithospermic acid purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Feb 20:31:101589.

    Treatment with Lithospermic acid (LA) or LA@ZIF-8 downregulated these protein levels, with LA@ZIF-8 showing stronger anti-inflammatory effects.

    Lithospermic acid purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Feb 20:31:101589.

    To explore the molecular mechanism of Lithospermic acid (LA)/ Lithospermic acid (LA)@ZIF-8 in reducing OA synovial macrophage inflammation, we performed genome-wide RNA-sequencing on LPS-stimulated RAW264.7 cells treated with LA.

    Lithospermic acid purchased from MedChemExpress. Usage Cited in: Mater Today Bio. 2025 Feb 20:31:101589.

    The inflammatory signaling pathways were significantly inhibited by Lithospermic acid (LA) treatment.

    Lithospermic acid purchased from MedChemExpress. Usage Cited in: Immunol Res. 2025 Feb 19;73(1):54.  [Abstract]

    Prior to incubation with LPS (1 µg/ml) for 24 h, the cells were pre-treated with Lithospermic acid (100 µM) for 1 h. Cells were fixed with paraformaldehyde followed by staining with crystal violet solution. The morphological changes in different groups were observed and captured with microscopy. Scale bars, 50 µM.

    Lithospermic acid purchased from MedChemExpress. Usage Cited in: Immunol Res. 2025 Feb 19;73(1):54.  [Abstract]

    Pre-treatment with Lithospermic acid (100 μM, 1 h) resulted in a marked decrease in ROS fluorescence intensity in BV2 cells.

    Lithospermic acid purchased from MedChemExpress. Usage Cited in: Immunol Res. 2025 Feb 19;73(1):54.  [Abstract]

    Pre-treatment with Lithospermic acid dose-dependently suppressed LPS-primed IL-6 mRNA transcription.

    View All NO Synthase Isoform Specific Products:

    View All Isoforms
    nNOS iNOS eNOS

    View All AMPK Isoform Specific Products:

    View All Isoforms
    NUAK1 NUAK2 AMPK AMPK α1β1γ1 AMPK α2β1γ1 AMPK α1β2γ1 AMPK α2β2γ1 BRSK1 BRSK2 HUNK AMPKα

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Lithospermic acid ((+)-Lithospermic acid) is a plant-derived polycyclic phenolic carboxylic acid isolated from Salvia miltiorrhiza, and has the anti-oxidative and hepatoprotective activity on carbon tetrachloride (CCl4)-induced acute liver damage in vitro and in vivo[1].

    Cellular Effect
    Cell Line Type Value Description References
    H9 IC50
    2 μM
    Compound: 7
    Inhibition of HIV1 integrase activity assessed as suppression of viral replication in human H9 cells
    Inhibition of HIV1 integrase activity assessed as suppression of viral replication in human H9 cells
    		[PMID: 27676157]
    In Vitro

    Lithospermic acid (100 μM, 24 h) promotes the expression of eNOS and the phosphorylation of AMPKα, activates Nrf2/HO-1 signaling pathways, exhibits antioxidant and anti-apoptotic activities[2].
    Lithospermic acid (16 μg/mL, 30 min) is the competitive inhibitor for xanthine oxidase, that inhibits uric acid production with an IC50 of 5.2 µg/mL, inhibits superoxide radicals (SOR) production with an IC50 of 1.08 µg/mL[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Lithospermic acid Related Antibodies

    Apoptosis Analysis[1]

    Cell Line: H9C2
    Concentration: 100 μM
    Incubation Time: 24 h
    Result: Inhibited apoptosis in H9C2.
    In Vivo

    Lithospermic acid (50 mg/kg, po for 6 days) exhibits cardioprotective efficacy against MI/R injury in mouse models[2].
    Lithospermic acid (10-30 mg/kg, po, single dose) exhibits uric acid lowering and anti-inflammatory effects in rats hyperuricemia and gouty arthritis models[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: C57BL/6 mouse MI/R injury models[2]
    Dosage: 50 mg/kg
    Administration: po for 6 days
    Result: Improved MI/R-induced cardiac dysfunction.
    Animal Model: Hyperuricemia and gouty arthritis model[3]
    Dosage: 10-30 mg/kg
    Administration: po, single dose
    Result: Reduced the serum uric acid and monosodium urate crystal-induced paw edema.
    Molecular Weight

    538.46

    Formula

    C27H22O12
    CAS No.
    Appearance

    Solid

    Color

    Off-white to light yellow

    SMILES

    O=C([C@@H]1[C@@H](C2=CC=C(O)C(O)=C2)OC3=C(O)C=CC(/C=C/C(O[C@@H](C(O)=O)CC4=CC=C(O)C(O)=C4)=O)=C13)O
    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Solvent & Solubility
    In Vitro: 

    DMSO : 100 mg/mL (185.71 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : 66.67 mg/mL (123.82 mM; Need ultrasonic)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.8571 mL 9.2857 mL 18.5715 mL
    5 mM 0.3714 mL 1.8571 mL 3.7143 mL
    View the Complete Stock Solution Preparation Table

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.75 mg/mL (5.11 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: ≥ 2.75 mg/mL (5.11 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.75 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (27.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 100 mg/mL (185.71 mM); Clear solution; Need ultrasonic

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    Purity & Documentation

    Purity: 99.56%

    SDS (393 KB)

    COA (257 KB) HNMR (132 KB) RP-HPLC (74 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMSO 1 mM 1.8571 mL 9.2857 mL 18.5715 mL 46.4287 mL
    5 mM 0.3714 mL 1.8571 mL 3.7143 mL 9.2857 mL
    10 mM 0.1857 mL 0.9286 mL 1.8571 mL 4.6429 mL
    15 mM 0.1238 mL 0.6190 mL 1.2381 mL 3.0952 mL
    20 mM 0.0929 mL 0.4643 mL 0.9286 mL 2.3214 mL
    25 mM 0.0743 mL 0.3714 mL 0.7429 mL 1.8571 mL
    30 mM 0.0619 mL 0.3095 mL 0.6190 mL 1.5476 mL
    40 mM 0.0464 mL 0.2321 mL 0.4643 mL 1.1607 mL
    50 mM 0.0371 mL 0.1857 mL 0.3714 mL 0.9286 mL
    60 mM 0.0310 mL 0.1548 mL 0.3095 mL 0.7738 mL
    80 mM 0.0232 mL 0.1161 mL 0.2321 mL 0.5804 mL
    100 mM 0.0186 mL 0.0929 mL 0.1857 mL 0.4643 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Lithospermic acid Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Lithospermic acid28831-65-4(+)-Lithospermic acidNO SynthaseAMPKKeap1-Nrf2Xanthine OxidaseApoptosisNitric oxide synthasesNOSAMP-activated protein kinaseXOInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Lithospermic acid
    Cat. No.:
    HY-N0823
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.